PILA PHARMA AB (5KC) Price & Analysis

0 Followers

5KC Stock Chart & Stats

€0.20

€0.09(20.09%)

At close: Jan 08 4:00 PM EST

€0.20

€0.09(20.09%)

Day’s Range― - ―

52-Week Range€0.09 - €0.26

Previous CloseN/A

Volume2.28K

Average Volume (3M)0.00

Market Cap

€5.30M

Enterprise Value€46.23M

Total Cash (Recent Filing)€15.90M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.44

Next Earnings

Aug 27, 2026

EPS Estimate

-0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.46

Shares Outstanding45,682,120

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.37

Price to Book (P/B)4.82

Price to Sales (P/S)63.25

P/FCF Ratio-7.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA zero-debt balance sheet materially reduces financial distress risk and preserves flexibility to fund R&D through equity or partnerships. Over 2–6 months this supports solvency during clinical work and makes the company a lower-credit-risk partner for collaborators.

Material Equity IncreaseA larger equity base provides a tangible buffer against operating losses and extends runway without immediate refinancing. This durable capital improvement supports continued development activity and improves credibility with investors and potential licensing partners.

Focused Clinical StrategyA narrow, science-driven focus on TRPA1 and a lead candidate (XEN-D0501) concentrates resources and expertise, increasing chances of meaningful progress. Structurally, a differentiated mechanism in metabolic disease can attract strategic partners and licensing opportunities long-term.

Bears Say

Persistent Negative Cash FlowConsistent multi-year negative operating and free cash flow signals ongoing cash burn that will require external funding to sustain development. Over months this structural outflow raises dilution and execution risk if capital markets tighten or fundraising terms worsen.

Widening Net LossesIncreasing annual losses indicate that operating leverage and cost control have not yet been achieved. Persistently larger deficits erode equity and amplify future financing needs, constraining the company’s ability to progress trials or scale without significant new capital or partnerships.

Small, Volatile Revenue BaseMinimal and inconsistent revenue provides little offset to R&D expense and leaves the business dependent on external financing. Structurally, lack of diversified, predictable income increases execution risk and limits self-funding capacity over the medium term.

5KC FAQ

What was PILA PHARMA AB’s price range in the past 12 months?

PILA PHARMA AB lowest stock price was €0.09 and its highest was €0.26 in the past 12 months.

What is PILA PHARMA AB’s market cap?

PILA PHARMA AB’s market cap is €5.30M.

When is PILA PHARMA AB’s upcoming earnings report date?

PILA PHARMA AB’s upcoming earnings report date is Aug 27, 2026 which is in 25 days.

How were PILA PHARMA AB’s earnings last quarter?

PILA PHARMA AB released its earnings results on Feb 26, 2026. The company reported -€0.033 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.033.

Is PILA PHARMA AB overvalued?

According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PILA PHARMA AB pay dividends?

PILA PHARMA AB does not currently pay dividends.

What is PILA PHARMA AB’s EPS estimate?

PILA PHARMA AB’s EPS estimate is -0.02.

How many shares outstanding does PILA PHARMA AB have?

PILA PHARMA AB has 45,682,120 shares outstanding.

What happened to PILA PHARMA AB’s price movement after its last earnings report?

PILA PHARMA AB reported an EPS of -€0.033 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.869%.

Which hedge fund is a major shareholder of PILA PHARMA AB?

Currently, no hedge funds are holding shares in DE:5KC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PILA PHARMA AB

Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating type 2 diabetes. PILA PHARMA AB (publ) was founded in 2014 and maintains its headquarters in Malmö, Sweden.